Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC.
Saved in:
| Title: | Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC. |
|---|---|
| Authors: | Heersche N; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands., Lanser DAC; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Muntinghe-Wagenaar MB; Department of Pulmonary Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Mohmaed Ali MI; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Ulas EB; Department of Pulmonary Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands., Trooster TMA; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands., de Jonge E; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands., Oomen-de Hoop E; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Paats MS; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Bahce I; Department of Pulmonary Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands., Croes S; Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Center, CARIM - School for Cardiovascular Disease, Maastricht, The Netherlands., Hendriks LEL; Department of Pulmonary Medicine, Maastricht University Medical Center, GROW - School for Oncology and Reproduction, Maastricht, The Netherlands., van der Wekken AJ; Department of Pulmonary Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Dingemans AC; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands., Huitema ADR; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pharmacology, Princess Máxima Center for Paediatric Oncology, Utrecht, The Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., van Schaik RHN; Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: a.mathijssen@erasmusmc.nl., Veerman GDM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. |
| Source: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2025 Apr; Vol. 20 (4), pp. 475-486. Date of Electronic Publication: 2024 Nov 29. |
| Publication Type: | Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
